Oct. 20 at 12:44 PM
$VRDN DRI terms: The Company will pay tiered royalties to DRI based on net sales of veligrotug, VRDN-003 and certain other related products (the “net sales”). The royalties consist of (i) 7.5% of annual U.S. net sales up to and including
$600 million, which royalties could increase to low-double digits if marketing approval for VRDN-003 is not received prior to a specified date, (ii) 0.8% of annual U.S. net sales above
$600 million and up to and including
$900 million, (iii) 0.25% of annual U.S. net sales above
$900 million and up to
$2.X billion, and (iv) no royalty owed for annual U.S. net sales in excess of
$2.X billion
